Back to top

pharmaceuticals: Archive

Sanghamitra Saha

3 Sector ETFs to Bet On Despite Soft November Jobs Data

These sector ETFs should gain post November jobs data.

FXH IYT XME FTXR

Zacks Equity Research

Roche's Tecentriq Gets FDA Approval for First-Line NSCLC

Roche's (RHHBY) Tecentriq in combination with Avastin obtains FDA nod for the initial treatment of NSCLC.

RHHBY BMY MRK GILD

Kinjel Shah

5 Top Drug/Biotech Merger & Acquisition Targets for 2019

Here are five stocks that are attractive and most likely to be takeout targets in 2019.

SNY ALXN CELG INCY BMRN VRTX ALNY

Zacks Equity Research

Mallinckrodt (MNK) to Separate Generics & Branded Businesses

Mallinckrodt (MNK) announces plans to split its generic and branded businesses into two different companies.

LLY BMY MRK MNK

Zacks Equity Research

Novartis Presents Additional Data on Breast Cancer Candidate

Novartis (NVS) presents supplementary data from phase III study on BYL719 in combination with Faslodex for the treatment of advanced breast cancer. The study scripts success in PFS.

MRK NVS AZN BMY

Zacks Equity Research

AstraZeneca's Imfinzi Fails in Head and Neck Cancer Study

AstraZeneca's (AZN) Imfinzi monotherapy and combination therapy fail to meet overall survival endpoint in phase III EAGLE study.

BMY AZN MRK INCY

Zacks Equity Research

Pharma Stock Roundup: Glaxo's TESARO Buyout & Horlicks Sale, ASH Cancer Data Updates

Glaxo (GSK) to buy TESARO and divest Horlicks brand to Unilever. ASH cancer presentations grab headilines.

PFE ABBV GSK JNJ NVS AZN RHHBY

Zacks Equity Research

Roche's Kadcyla Halves Death Risk in Breast Cancer Study

Roche (RHHBY) announces detailed data from a late-stage study on Kadcyla in early breast cancer patients. Kadcyla reduces risk of disease recurrence by 50% compared to Herceptin.

RHHBY NVS IMGN TEVA

Zacks Equity Research

AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study

IDMC recommends AbbVie (ABBV) to stop enrolment in a late-stage study on its small cell lung cancer candidate, Rova-T.

ABBV MRK JNJ RHHBY

Zacks Equity Research

Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger

Shire's (SHPG) pending acquisition by Takeda Pharmaceuticals for $62 billion gets approval from shareholders of both the companies.

AGN INCY BMRN SHPG

Ryan McQueeney

Mixed Trade War Signals, the Moonves Scandal, & CVS' Drug Price Plan

Ryan McQueeney discusses the latest drama in the U.S.-China trade war, new developments in Les Moonves' departure from CBS, and a new drug pricing plan from pharmacy giant CVS.

CBS CVS

Zacks Equity Research

J&J's Blood Cancer Drugs Succeed in Label Expansion Studies

J&J (JNJ) presents positive data from late-stage studies evaluating its blood cancer drugs, Imbruvica and Darzalex, in the first-line setting at ASH.

ABBV JNJ RHHBY CELG

Zacks Equity Research

Mylan Expands Recall of Valsartan to All Unexpired Lots

Mylan (MYL) expands recall of batches of blood pressure medicine in the United States to include all Valsartan-based products within expiry.

JNJ MRK TEVA MYL

Zacks Equity Research

The Zacks Analyst Blog Highlights: Verizon, Eli Lilly, Accenture, VMware and Schwab

The Zacks Analyst Blog Highlights: Verizon, Eli Lilly, Accenture, VMware and Schwab

LLY VZ VMW SCHW ACN

Zacks Equity Research

Roche's Tecentriq Combination Gets Priority Review by FDA

The FDA accepts and grants Priority Review to Roche's (RHHBY) sBLA for Tecentriq in combination with carboplatin and etoposide for the initial treatment of patients withextensive-stage small cell lung cancer.

RHHBY NVS BMY AMGN

Zacks Equity Research

J&J Strikes Deal with argenx to Co-Develop Cancer Antibody

Johnson & Johnson (JNJ) inks a global deal with Europe's argenx to jointly develop and globally commercialize the latter's prospective antibody, cusatuzumab.

JNJ BMY CELG ARWR

Zacks Equity Research

Roche Announces Positive Data on Venclexta/Venclyxto at ASH

Roche (RHHBY) announces new Venclexta/Venclyxto data that demonstrate deep responses in two of the most common types of leukaemia.

BMY RHHBY ABBV TEVA

Zacks Equity Research

Company News For Dec 4, 2018

Companies In The News Are: TSRO,GSK,TRCO,NXST,VNDA,GBT

GSK NXST TRCO GBT VNDA TSRO

Tirthankar Chakraborty

5 Top Dividend Aristocrats to Buy in December

With things not looking up for the stock market this December, it's prudent to invest in dividend aristocrats for their risk-adjusted returns.

APD MKC WBA VFC ADP

Zacks Equity Research

FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101

The FDA accepts Novartis' (NVS) BLA for AVXS-101 and grants Priority Review to the same.

NVS BIIB AXON QURE

Zacks Equity Research

Glaxo to Buy Zejula Maker TESARO for $5.1B, Stock Down 8%

Glaxo (GSK) announces definitive deal to buy TESARO.

AZN GSK CLVS TSRO

Zacks Equity Research

Glaxo to Sell India's Popular Horlicks Brand to Unilever

Glaxo (GSK) divests its Horlicks and other nutrition products in India to Unilever.

NVS GSK KO UL

Tirthankar Chakraborty

New Strong Buy Stocks for December 4th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

TECD IIIV HCHC CASY BHC

Zacks Equity Research

AbbVie Settles With Pfizer for Humira Biosimilar in U.S.

AbbVie (ABBV) strikes a deal with Pfizer to launch its biosimilar of Humira in the United States in November

ABBV PFE AMGN MYL

Zacks Equity Research

Shire's Takhzyro Gets European Nod for Hereditary Angioedema

Shire's (SHPG) gets European approval for Takhzyro subcutaneous injection, for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.

MRK BMY GILD SHPG